New cancer drug GI-108 enters human trials for advanced tumors

NCT ID NCT07172802

Recruiting now Disease control Sponsor: GI Innovation, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then test how well it works in a larger group. About 76 participants will receive the drug intravenously every three weeks for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GI-108 (a bispecific fusion protein targeting CD73 and IL-2)
What this could lead to: If successful, this could lead to a new treatment option for several advanced cancers, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early-phase trial with only 76 participants, so safety and effectiveness are not yet proven. The drug may cause immune-related side effects or fail to show meaningful anti-tumor activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma malignant pancreatic neoplasm metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic neoplasm renal cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HEAD AND NECK (HNSCC) METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC CANCER RENAL CELL CARCINOMA (RCC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea

Contact Email: •••••@•••••
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••
Yonsei University Health System, Severance Hospital
RECRUITING

Seoul, 03722, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.